Tilray Imports Bulk Supply of Medical Cannabis Oil Into The United Kingdom

CANADA: Tilray, a global pioneer in cannabis research, cultivation, production and distribution, today announced it has imported medical cannabis oral solutions in bulk into the United Kingdom from its Good Manufacturing Practices (GMP)-certified facility in Canada. This export allows Tilray to provide authorized U.K. patients in need with a locally maintained supply of medical cannabis oral solutions.
 
In September 2018, Tilray announced the successful import of Tilray 2:100 medical cannabis oil for a pediatric patient in need in the United Kingdom. Tilray’s 2:100 cannabis oil was supplied via a government-approved special access program following the U.K. Home Secretary’s historic announcement that declared prescriptions of cannabis-derived medicines legal for patients with an exceptional clinical need.
 
“As demand ramps up in the U.K., Tilray is well positioned to be a leading supplier of medical cannabis products,” says Sascha Mielcarek, Managing Director of Tilray Europe. “Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients’ quality of life. We’re pleased to reaffirm our commitment to delivering medical cannabis to patients in the U.K. and look forward to offering a variety of GMP-certified, pharmaceutical-grade products in the coming months.”
 
Tilray has six medical cannabis products approved for medical use in the U.K. that can be made available to patients with medical cannabis prescriptions obtained through private practice or the National Health Service. Tilray anticipates supplying a variety of cannabidiol (CBD)-dominant, tetrahydrocannabinol (THC)-dominant and balanced oral solutions for patients looking to use medicines derived from cannabis.
 
“This bulk import of Tilray medical cannabis oral solutions provides patients in need access to a sustained supply of GMP-certified, high quality medical cannabis,” says Catherine Jacobson, Tilray’s Vice President of Medical and Regulatory Affairs. “This is an important step in improving access in the U.K. Tilray will continue to advocate for reasonable patient access to medical cannabis in the U.K. and countries around the world.”

Leafly Pickup Expands Into Canada

CANADA: Leafly, the leading technology platform that helps people discover and find cannabis, today announced the launch of Leafly Pickup in Canada. Leafly Pickup allows consumers to browse the menus of participating cannabis retailers, reserve products online, and then pick up and purchase products in-store directly from the retailer.

Leafly Pickup is available now with leading Canadian recreational cannabis retailer Spiritleaf, a brand established by Inner Spirit Holdings Ltd. (CSE: ISH). Leafly Pickup will initially be available at Spiritleaf’s Alberta and Saskatchewan retail cannabis stores, including new flagship locations in Calgary and Edmonton, Alberta. Additional retailers will follow Spiritleaf and launch the service in coming weeks and months. Canada is the first country to offer the service outside the United States, which first launched it in March 2018.

“Leafly Pickup is truly a consumer-first technology that exists to help people find the cannabis products they want coupled with the information they need to make informed decisions,” said Leafly CEO Tim Leslie. “We’re proud of the momentum Leafly Pickup has in the U.S. It’s improving the consumer experience and it’s boosting revenue for retail partners. Leafly Pickup is just another way we’re showing Canadians that Leafly is their destination for cannabis discovery and education.”

“Leafly Pickup is the latest example of how we leverage technology to solve business issues in the cannabis value chain – specifically, by increasing consumer access and the appeal of the legal market,” said Jo Vos, Managing Director, Leafly Canada. “We’re proud to launch this new feature with the fantastic team at Spiritleaf – just in time for Canada Day.”

Spiritleaf has franchise-owned or licensed retail cannabis stores operating in Brooks, Lethbridge, St. Albert, Calgary (Stonegate) and Edmonton (Argyll), Alberta; Moose Jaw, Saskatchewan; and Kingston, Ontario. Spiritleaf’s first corporate-owned retail cannabis stores are expected to open this week in Calgary (Beltline) and Edmonton (Old Strathcona), Alberta.

 

iCAN: Israel-Cannabis CEO Saul Kaye Comments on New Israeli Cannabis Initiatives

ISRAEL: Kupat Holim Meuhedet, Israel’s third largest health maintenance organization (HMO), announced yesterday that it was opening an internal cannabis unit using a digitalized system that will allow for significantly faster medical cannabis approval for patients in need.

In the framework of the new independent unit, the family doctor will transfer the request of the Meuhedet patient with a recommendation to the unit within the fund, which will approve the request. The process will shorten the generally long wait that typifies the unit of the Ministry of Health.  As a result, other health funds are considering the possibility of setting up similar units.

“We congratulate Meuchedet on their forward-thinking attitude to cannabis medicine and breaking the barriers that currently exist in Israel for patient access. For too long the HMOs have been complacent in the long and complicated process of obtaining medical cannabis in Israel. I hope to see the next news that they are covering the cost of cannabis for reimbursement as part of the medical system in Israel.  Meuchedet is the most supportive Israeli health fund. They have the most doctors who understand the importance of medical cannabis treatment and have the knowledge to prescribe it,” said iCAN: Israel-Cannabis CEO Saul Kaye.

In addition, also yesterday, Israeli news organizations reported that Prime Minister Benjamin Netanyahu will support a bill tabled by Likud MK Sharren Haskel that would, in effect, legalize cannabis by allowing all Israelis to grow one cannabis plant for personal consumption.  Dealing cannabis would remain illegal.

“No one should be criminalized for growing a cannabis plant and using the leaves as they see fit.  This is an important step in the process of decriminalizing cannabis in Israel and I hope this legislation passes soon after the Knesset is back from its summer recess. I have worked closely with MK Haskel on all of her cannabis initiatives and wish her well in the upcoming elections as Israel’s true cannabis voice in the Government,” said Kaye.

Tilray Hosts Official Ribbon-Cutting Ceremony At European Union Campus For Medical Cannabis Production and Distribution

The 250,000 square-foot facility located in Cantanhede, Portugal serves as the hub for Tilray’s cultivation, processing, distribution and research of medical cannabis products in Europe

CANADA: Tilray, a global pioneer in the research, cultivation, production and distribution of cannabis today celebrated the official opening of its European Union (EU) Campus located in Cantanhede, Portugal. Tilray CEO Brendan Kennedy, global senior leaders and the EU Campus Team welcomed guests from all over the world including international healthcare professionals, government officials and local dignitaries to celebrate the inauguration of the company’s European production and distribution centre.   
 
For the event, which followed Tilray’s successful outdoor harvest last year and greenhouse harvest earlier this year, guests were invited to attend a ribbon-cutting ceremony and tour Tilray’s state-of-the-art facility. 

Tilray’s EU Campus in Portugal is a multi-faceted production facility that includes indoor, outdoor and greenhouse cultivation sites, as well as research labs, processing, packaging and distribution sites for medical cannabis and cannabinoid-derived medical products. To date, Tilray has invested approximately €20 million in the facility, which totals approximately 250,000 square-feet with additional room to expand. Tilray’s EU Campus also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray’s EU Campus currently employs more than 100 professionals, and that number is expected to double by the end of 2019, with production ramping up and multiple harvests anticipated in the coming months. 
 
“We’re thrilled to celebrate another milestone as we continue to expand our global presence and pioneer the future of the cannabis industry. We are grateful for the warm welcome we’ve received from Portugal and the city of Cantanhede,” says Brendan Kennedy, Tilray CEO. “We’re looking forward to utilizing Tilray’s EU Campus to serve the European Union medical cannabis markets with high-quality, pharmaceutical-grade medical cannabis products.”
 
Tilray announced a successful harvest from its EU Campus in February 2019 with multiple harvests expected in the coming months. Tilray looks forward to supplying patients in Europe from its EU Campus when it receives GMP certification.
 

 

 

FSD Pharma Receives Cannabis Sales License From Health Canada

CANADA: FSD Pharma Inc. announced that its wholly-owned subsidiary FV Pharma Inc. has received its Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license went into effect on April 18, 2019.

The license allows the current FSD facility to supply and sell cannabis products. The company anticipates receiving the amended sales license that will include the sale of dried and fresh cannabis flower in the near future.

Dr. Raza Bokhari, Executive Co-Chairman and CEO congratulated the FSD Pharma team, shareholders and stakeholders on this much anticipated achievement. Dr. Bokhari stated, “Our sales license is a key development for FSD Pharma and a huge success and step forward for our Cobourg Facility.”

“We have achieved this milestone thanks to the efforts of our dedicated team. We are exceptionally proud of this achievement and look forward to accelerating our efforts,” commented Dr. Sara May, President of FV Pharma Inc.

Zeeshan Saeed, President and Founder, added, “The granting of our sales license allows FSD to serve the growing medicinal use markets in Canada. We intend to quickly scale up production at our current facility, while continuing to build out the plant to add additional grow capacity. In addition, our sales license opens the door for our partner Canntab Therapeutics to commence sales of its suite of novel cannabis oral dose delivery platforms, including CBD and THC capsules, in Canada and global markets. We expect that this will provide an immediate benefit to both parties, since FSD is entitled to a share of Canntab’s revenue from sales as a result of the collaboration and profit sharing agreement that we entered into this past fall.”

Anthony Durkacz, Founder and Executive Co-Chairman of the board speaking on behalf of the FSD Pharma Board of Directors stated, “We are proud of the leadership at FSD Pharma. This industry is transforming very rapidly and the leadership has positioned the company well to generate top tier revenue from our medicinal grade cannabis production.”

iCAN Secures Financing Through A Convertible Loan Of CAD $4 million (US $3 million)

ISRAEL: iCAN: Israel-Cannabis has announced that it has issued a secured convertible loan in the amount of CAD $4,000,000 to a group of investors led by Plaza Capital.
 
The principal amount of each Convertible Security, plus accrued interest shall be convertible, for no additional consideration, into common shares of the Company at the option of the holders at any time following the completion of a subsequent Qualified Financing and prior to the close of business on the Maturity Date, at a conversion price equal to the price per share based on a valuation of US $20M. The Convertible Securities shall bear interest at a rate of 8.0% per annum from the date of issue and shall be accrued into the note. 
 
Saul Kaye, CEO of iCAN: Israel-Cannabis, stated: “We are excited at the opportunities this financing round will create for iCAN and proud to have Plaza Capital join our solid investor base. With the success of CannaTech Davos and Panama so far in 2019, we are now well positioned to take our premier events to even more countries and continue to push the medicalization of cannabis around the world, with Cape Town already planned for late 2019. Our flagship event in Tel Aviv this week, once again sold out, and brought together the best Cannabis minds from around the world, showcasing Israel’s leadership in research and technology. iCAN’s unique position at the forefront of this exploding industry creates a wave of opportunities and this strategic financing will grow our iCAN:Serve and iCAN:Incubate portfolios.
 
Jesse Kaplan and Sruli Weinreb, Managing Partners at Plaza Capital added: “We were hugely impressed with iCAN’s performance and leadership at the recent CannaTech Panama event and see immense opportunity in their global positioning and pipeline of new technologies. Saul Kaye is front and center of the global cannabis economy and we are thrilled to support him and iCAN.”
 
The investment funds will be used to acquire and incubate cannabis-related businesses and anchor iCAN Incubate with a broad portfolio of new cannabis technologies. The funds will also provide an injection into iCAN’s conference platform CannaTech to continue to expand the pipeline of opportunities and extend the global cannabis footprint.
 
Shwergold Aharonson & Co. acted as sole legal advisory to iCAN while Plaza Capital was advised by Garfinkle Biderman in Canada and Yigal Arnon & Co. in Israel

Tilray Expands Manufacturing Capacity With New Processing License From Health Canada

Newly-acquired Natura Naturals Inc. located in Leamington, Ontario obtains processing license, allowing it to produce a wide range of cannabis form factors for the Canadian market

CANADA: Natura Naturals Inc., a wholly-owned subsidiary of Tilray, Inc. and High Park Holdings Ltd., has received a standard processing license under the Cannabis Act. The Natura greenhouse facility, which previously held a standard cultivation license, will now be able to manufacture a wide range of cannabis form factors from cannabis starting material, including oil, pre-rolls, and novel formats such as topicals and edibles.

Natura, which will operate under High Park Gardens Inc., was acquired by Tilray in February 2019 to serve the adult-use and medical cannabis market in Canada alongside Tilray’s existing operations. The site is a 662,000 square-foot greenhouse facility with 155,000 square-feet licensed for cultivation. The addition of a standard processing license means that High Park Gardens will be able process cannabis raw material cultivated on site – as well as raw material sourced from other cannabis licensees – into a variety of value-add product formats. This development provides Tilray’s facilities additional flexibility in the manufacture of products for the Canadian cannabis market, and in the development of novel products in preparation for legalization of additional cannabis products, including tinctures, concentrates and edibles, in Canada later this year.

High Park Gardens will work closely with Tilray’s existing operations in British Columbia and Ontario: High Park Farms Ltd., a cultivation and processing facility featuring 13 acres of greenhouse space on 100 acres of property in Enniskillen, Ontario; High Park processing facility, a 56,000 square-foot processing and R&D facility in London, Ontario and Tilray Canada Ltd., a cultivation, research and processing facility located in Nanaimo, British Columbia. All sites are actively engaged in the cultivation, manufacture, and sale of cannabis products for the Canadian cannabis market.

“The acquisition of High Park Gardens in February allowed us to significantly increase our production footprint,” says Greg Christopher, EVP Operations, Tilray. “With this additional licensing, we’re pleased to have expanded Tilray and High Park’s capacity to develop and manufacture high-quality branded products for the Canadian market.”

 

Aphria Receives Health Canada License Amendment, Approving Fully Expanded Production At Aphria One

CANADA: Aphria has announced that Health Canada has granted the Company its license amendment, permitting Aphria to commence production in an additional 800,000 square feet of facilities at its Aphria One location, as part of the Company’s completed Part IV and Part V expansions.

aphria logo“This is a major milestone for Aphria on its path to becoming a leading global cannabis producer, as well as a positive development greatly anticipated by the Canadian cannabis industry,” said Irwin D. Simon, Interim CEO of Aphria. “Aphria’s progress expanding production and automation is essential to our strategy of securing scale and long-term advantages that enable the evolution of the cannabis industry through product and brand innovation. With Aphria One, we now have the ability to expand our production capacity by over three times.”

Simon concluded, “We are ready to hit the ground running and look forward to alleviating industry-wide supply constraints with our greatly expanded production capacity and sophisticated, proprietary automation technology that will ensure Aphria remains at the forefront of cannabis cultivation and innovation. In anticipation of Health Canada’s approval, we had allocated a portion of our previously approved capacity to mother and vegetative plants that will be used as the initial growing crops in Part IV and Part V. As a result of these measures, growing operations in the expanded facilities are expected to commence without delay. By this Friday, we will move swiftly to establish nearly 22,000 plants in the Part IV and Part V expansion, with an additional 12,000 plants added each week thereafter until we reach full crop rotation.”

Industry-Leading Automation

The completed Part IV & Part V expansions at Aphria One bring industrial-scale horticulture production technology to cannabis cultivation. While critical phases such as initial cuttings, trimming and pruning mature plants will be performed by hand, the in-house designed technology will automate key steps, including:

  • Transplanting cuttings
  • Transporting plants through harvesting
  • De-budding & rough trimming
  • Drying & curing
  • Waste disposal

Aphria One

The 700,000 square foot Part IV Expansion and the 100,000 square foot Part V expansion represent the completion of Aphria’s five-part expansion at Aphria. Once in full rotation, Part IV and Part V will produce on an incremental annualized basis 80,000 kg bringing the total annualize production capacity at Aphria One to 110,000 kg.

Investors That Purchased FSD Pharma Securities May Have An Opportunity To Recover Their Financial Losses.

CANADA: Morganti & Co., P.C., a cross border shareholder’s rights law firm, has commenced a shareholder class action lawsuit against FSD Pharma Inc. for publishing investor documents containing misrepresentations of material fact about the status of its joint venture with Auxly Cannabis Group Inc. between September 29, 2018, and January 7 or February 6, 2019.

The shareholders allege that these misrepresentations resulted in the market price and value of HUGE’s securities being artificially inflated or otherwise over-valued as reflected by a portion of the drop in the market price after the release of the corrective disclosures on January 7 and February 6, 2019.

Investors that purchased HUGE’s securities may have an opportunity to recover their financial losses. Investors are encouraged to contact Morganti & Co. to register their interest and determine their financial losses, if any. Investors will not be charged for this service.

International Hemp Oil Company, Functional Remedies, Acquires New Lab, Increasing Production Capacity Ten-Fold

COLORADO: Functional Remedies, vertically integrated manufacturer of whole-plant hemp oil products, announced a major expansion of its lab and production facility from 2,000 square feet to a new 25,000-square-foot facility located in Louisville, CO to meet the rapidly growing demand for its products across the U.S. and globally. Additionally, Functional Remedies recently moved into new 4,000-square-foot executive offices to house its expanding team.

“We are excited with our rapid growth, and our latest production and office expansions will help us continue building the most-advanced operations in the industry to meet the increasing demands for our full-spectrum hemp products domestically and internationally,” said Functional Remedies CEO Anthony Mazzotti. “We are fully executing on our aggressive 2019 plans and exceeding consumer expectations of how highly efficacious, full-spectrum hemp oil can impact health and wellness.”

Functional Remedies also recently announced that it signed five new agreements with natural retail broker networks to expand the distribution footprint of its products from 21 to 48 U.S. states. This comes at a time when the global industrial hemp market size is expected to reach USD $10.6 billion by 2025 and expand at a CAGR of 14 percent during the forecast period, according to a new report by Grand View Research, Inc.

“Our state-of-the-art 25,000-square-foot laboratory houses the production of the industry’s only hand-pressed, full-spectrum hemp oil using a proprietary whole-plant, lipid infusion process,” said Functional Remedies Chief Science Officer Tim Gordon. “Consumer demand is growing faster than education or regulatory structures can keep up, and many inferior products are willingly filling that grey market void. Functional Remedies’ mission is to continue educating consumers on the difference between lipid-infused, full-spectrum hemp oil and the majority of other products that are actually CBD isolate and concentrates made using harsh, CO2 extraction methods. Many of these products are mislabeled as full-spectrum which only adds to consumer confusion,” Gordon added.